Press Release_ENHERTU Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
第一三共在中國已開展了三十年的業務，我們提供的醫藥產品覆蓋各治療領域.
